Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,522 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07298122Recruiting
Heart imaging for hidden clots in ESUS stroke with left ventricular disease
This study uses advanced heart scans (MRI or CT) to look for blood clots in the heart of people who had a stroke with an unclear cause, specifically if they also have a mild heart condition affecting the left ventricle. The goal is to find hidden clots that might be causing strokes.
Milan, LombardyAges 18 years+ - NCT07291063Recruiting
Immunotherapy plus chemo for advanced bile duct or gallbladder cancer
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT07292961Recruiting
Exercise program for people with scleroderma
This study tests if a special exercise program based on your body and mind can help people with scleroderma feel better. It is for both children (ages 7-18) and adults.
Ankara, AltındağAges 7 years+ - NCT07291076RecruitingPhase 1/Phase 2
Study of Pumitamig with Ipilimumab for first-line advanced liver cancer
This trial tests a new drug called pumitamig, either alone or with another drug (ipilimumab), for people with advanced liver cancer that hasn't been treated yet. The goal is to see if these drugs can help shrink or control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07274085RecruitingPhase 1
Study of HDM2017 for advanced solid tumors
This trial tests a new drug called HDM2017 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT06891742RecruitingPhase 1
A study of a new cell therapy for advanced liver cancer
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18–75 - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT07261501Recruiting
Antibacterial dressing for chronic wounds
This study tests a new absorbable wound dressing that fights bacteria to help heal chronic wounds that haven't improved for at least a week. It might be a good option if you have a wound that's infected or has bacteria on it and is between the size of a coin and a small plate.
Beijing, Beijing MunicipalityAges 1.5 years–80 years - NCT07258979RecruitingPhase 1/Phase 2
YL201 and Toripalimab with or without Cisplatin for Nasopharyngeal Cancer
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07258121RecruitingPhase 1/Phase 2
ZGGS34 for Advanced Solid Tumors Targeting MUC17
This trial tests an experimental drug called ZGGS34 that targets a protein (MUC17) found on some cancer cells. It is designed for people with advanced solid tumors (stomach, pancreas, colorectal, or other) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–75 - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT06878222RecruitingPhase 2
Testing an immunotherapy combo before surgery for cervical cancer
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
ShanghaiAges 18–75 - NCT07247227Recruiting
Sugemalimab plus chemotherapy for advanced lung cancer
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07247175RecruitingPhase 2
Testing force feedback in robotic prostate cancer surgery
This trial is looking at whether a new force-feedback feature in the da Vinci robotic system helps surgeons learn and operate more safely when removing the prostate for prostate cancer.
SoeulAges 19 years+ - NCT07231211RecruitingPhase 1/Phase 2
Testing SHR-4610 for advanced solid tumors
This trial tests a new drug called SHR-4610 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and may be an option if you have a measurable tumor and are generally in good health.
Hangzhou, ZhejiangAges 18–75 - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT07227896Recruiting
Study of a new pump treatment for advanced Parkinson's
This study looks at a new pump treatment (foslevodopa/foscarbidopa) for people with advanced Parkinson's who are having motor fluctuations. It aims to see if it improves quality of life when started earlier in the advanced stage.
Georgetown, TexasAges 18–80 - NCT07222397Recruiting
Laser treatment for deep wrinkles around the mouth
This study tests a special laser to treat deep lines and wrinkles around the mouth. It may help if you are between 50 and 80 years old and have fair to light brown skin.
Houston, TexasAges 50–80 - NCT07221851RecruitingPhase 3
Weekly vs daily growth hormone for short stature in children
This trial tests a weekly growth hormone injection (lonapegsomatropin) compared to the standard daily growth hormone shot in children with short stature due to certain conditions. It aims to see if the weekly shot works as well or better and is safe.
Palo Alto, CaliforniaAges 2–17 - NCT06860477RecruitingPhase 2
Freezing therapy plus targeted drugs vs. chemotherapy for advanced bile duct cancer
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,522 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.